What is Zacks Research’s Estimate for CRL Q2 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research decreased their Q2 2026 earnings estimates for Charles River Laboratories International in a report released on Thursday, April 10th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.46 for the quarter, down from their previous forecast of $2.67. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the business earned $2.46 EPS. The business’s revenue was down 1.1% on a year-over-year basis.

A number of other equities analysts have also issued reports on the company. Mizuho cut their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 9th. Barclays reduced their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. UBS Group reissued a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Finally, Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $182.00.

Charles River Laboratories International Trading Up 6.7 %

NYSE:CRL opened at $106.41 on Monday. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15. The business’s 50-day simple moving average is $155.52 and its 200 day simple moving average is $176.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market cap of $5.23 billion, a price-to-earnings ratio of 709.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of CRL. Patriot Financial Group Insurance Agency LLC increased its stake in Charles River Laboratories International by 12.8% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,706 shares of the medical research company’s stock valued at $257,000 after buying an additional 194 shares during the period. Impact Capital Partners LLC increased its stake in shares of Charles River Laboratories International by 12.2% during the first quarter. Impact Capital Partners LLC now owns 2,567 shares of the medical research company’s stock valued at $386,000 after acquiring an additional 280 shares during the period. Veracity Capital LLC raised its holdings in Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company’s stock worth $496,000 after purchasing an additional 107 shares in the last quarter. Heritage Family Offices LLP lifted its position in Charles River Laboratories International by 10.0% in the first quarter. Heritage Family Offices LLP now owns 1,689 shares of the medical research company’s stock worth $254,000 after purchasing an additional 153 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC boosted its stake in Charles River Laboratories International by 6.7% during the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 3,843 shares of the medical research company’s stock valued at $578,000 after purchasing an additional 240 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).